During a two-hour experimental chat with a therapist chatbot character, it “actively encouraged me to disregard my ...

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma’s latest deal to settle ...

Restrictions on gender-affirming care for minors consistently allow exceptions for minors with intersex traits, a new study ...

Most Medicare enrollees will face premiums that are 10% higher next year, creating budget anxiety for millions of seniors.

Merck agreed to buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal, as the ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Jenna Norton, a vocal critic of Trump administration actions at the NIH, was abruptly placed on administrative leave this ...

Weight loss drugs have skyrocketed in prevalence in recent years, according to a new KFF poll on GLP-1 drugs and drug prices.

A strategic and financial recalibration on psychiatric drug development brings profound implications for investors, insurers, ...

A closely watched next-generation blood thinner being developed by Bristol Myers Squibb and Johnson & Johnson failed in one of three late-stage trials.

Merck is buying Cidara Therapeutics for $9.2B, picking up an experimental flu therapy as it looks to broaden its pipeline.